JP2021511054A5 - - Google Patents

Info

Publication number
JP2021511054A5
JP2021511054A5 JP2020540347A JP2020540347A JP2021511054A5 JP 2021511054 A5 JP2021511054 A5 JP 2021511054A5 JP 2020540347 A JP2020540347 A JP 2020540347A JP 2020540347 A JP2020540347 A JP 2020540347A JP 2021511054 A5 JP2021511054 A5 JP 2021511054A5
Authority
JP
Japan
Prior art keywords
item
hpv
peptide
pool
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020540347A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511054A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/000131 external-priority patent/WO2019145792A1/en
Publication of JP2021511054A publication Critical patent/JP2021511054A/ja
Publication of JP2021511054A5 publication Critical patent/JP2021511054A5/ja
Priority to JP2025093322A priority Critical patent/JP2025131713A/ja
Pending legal-status Critical Current

Links

JP2020540347A 2018-01-24 2019-01-23 Ｈｐｖ免疫療法 Pending JP2021511054A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025093322A JP2025131713A (ja) 2018-01-24 2025-06-04 Ｈｐｖ免疫療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862621279P 2018-01-24 2018-01-24
US62/621,279 2018-01-24
PCT/IB2019/000131 WO2019145792A1 (en) 2018-01-24 2019-01-23 Hpv immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025093322A Division JP2025131713A (ja) 2018-01-24 2025-06-04 Ｈｐｖ免疫療法

Publications (2)

Publication Number Publication Date
JP2021511054A JP2021511054A (ja) 2021-05-06
JP2021511054A5 true JP2021511054A5 (enExample) 2022-01-31

Family

ID=67395339

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020540347A Pending JP2021511054A (ja) 2018-01-24 2019-01-23 Ｈｐｖ免疫療法
JP2025093322A Pending JP2025131713A (ja) 2018-01-24 2025-06-04 Ｈｐｖ免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025093322A Pending JP2025131713A (ja) 2018-01-24 2025-06-04 Ｈｐｖ免疫療法

Country Status (7)

Country Link
US (1) US20210046114A1 (enExample)
EP (1) EP3743436A4 (enExample)
JP (2) JP2021511054A (enExample)
CN (1) CN111868074A (enExample)
AU (2) AU2019213286A1 (enExample)
CA (1) CA3088837A1 (enExample)
WO (1) WO2019145792A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4125949A4 (en) * 2020-03-23 2024-05-22 The Council of the Queensland Institute of Medical Research COMPOSITIONS AND METHODS FOR TARGETING HPV-INFECTED CELLS
WO2025088530A1 (en) * 2023-10-24 2025-05-01 Treadwell Therapeutics T cell receptors and methods of use thereof
WO2026044351A1 (en) * 2024-08-28 2026-03-05 The Council Of The Queensland Institute Of Medical Research Hpv antigenic composition and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
US20040171081A1 (en) * 2001-11-23 2004-09-02 Abraham Mittelman Antigens
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
JP2005533855A (ja) * 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
WO2004105681A2 (en) * 2003-04-28 2004-12-09 Innogenetics N.V. Cd4+ human papillomavirus (hpv) epitopes
EP1708745B1 (en) * 2003-12-23 2012-04-18 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
JP2007528838A (ja) * 2003-12-24 2007-10-18 ライデン ユニバーシティ メディカル センター 腫瘍特異的ワクチンとしての合成タンパク質
EP1732598A4 (en) * 2003-12-31 2009-08-26 Pharmexa Inc TRIGGERING CELLULAR IMMUNE RESPONSES TO THE HUMAN PAPILLOVIRUS USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
US8252893B2 (en) * 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
CL2008000249A1 (es) * 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
WO2008145685A1 (en) * 2007-05-31 2008-12-04 Genimmune N.V. Hpv polyepitope constructs and uses thereof
GB0710538D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
BR112014014591A8 (pt) 2011-12-12 2017-07-04 Baylor College Medicine processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs
EP2802356A1 (en) * 2012-01-13 2014-11-19 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
EP2883550A1 (en) * 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Novel promiscuous HPV16-derived T helper epitopes for immunotherapy
DK3271382T3 (da) * 2015-03-16 2020-05-04 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Fremgangsmåde til detektion af nye immunogene T-celleepitoper og isolering af nye antigenspecifikke T-cellereceptorer ved hjælp af et MHC-cellebibliotek
CN117018170A (zh) * 2016-06-20 2023-11-10 Isa制药有限公司 肽疫苗制剂
SG11202008539YA (en) * 2018-03-06 2020-10-29 Precigen Inc Human papillomavirus vaccines and uses of the same

Similar Documents

Publication Publication Date Title
US20250188145A1 (en) Tcr and peptides
Hörig et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7. 1 co-stimulatory molecule
RU2721574C2 (ru) Вакцинная композиция против злокачественной опухоли
JP5934897B2 (ja) Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
US20130028915A1 (en) Dendritic cell (dc)-vaccine therapy for pancreatic cancer
US20130217122A1 (en) Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
CN107636152A (zh) 通过mhc细胞文库检测新免疫原性t细胞表位和分离新抗原‑特异性t细胞受体的方法
JP2012529283A (ja) 共有ｈｌａ−ｂ＊０７０２エピトープの同定、最適化および免疫療法のための使用
JP2019520332A5 (enExample)
TWI374031B (enExample)
CN114302962B (zh) 特异性针对来源于ebv抗原的tcr构建体
Lyu et al. A novel and simple method to produce large amounts of recombinant soluble peptide/major histocompatibility complex monomers for analysis of antigen-specific human T cell receptors
Bright et al. SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients
CN111138521B (zh) 源自于afp抗原的短肽
CN114853880A (zh) Wt1抗原特异性t细胞受体及其抗肿瘤用途
JP6255360B2 (ja) 共有ｈｌａ−ｂ＊０７０２エピトープの同定、最適化および免疫療法のための使用
NL2034657B1 (en) RCN1-derived TEIPP neoantigens and uses thereof
NL2034658B1 (en) TIMP3-derived TEIPP neoantigens and uses thereof
EP3055322B1 (en) Ubiquitinylated proteins
CN111138522B (zh) 衍生自afp的肿瘤抗原短肽
Yano et al. Correlation between Direct Binding Ability of SyntheticT. gondiiSAG1 Peptides to HLA-A2 Measured by a Sensor for Surface Plasmon Resonance and Antigenicity of the Peptides forT. gondii-Infected Cell-Specific CTL
CN112300261B (zh) 一种衍生自afp的肿瘤抗原短肽
CN110862449B (zh) 衍生自ssx的肿瘤抗原短肽
De Leo p53-based immunotherapy of cancer
EP1709971A1 (en) Peptide antigens useful for the prophylaxis, treatment and diagnosis of poxvirus infections